Date of Publication: 30-01-2026
INTELLIGENCE OVERVIEW
Agency: European Medicines Agency (EMA)
Product: Neurocrine Netherlands B.V. – Efmody (Hydrocortisone)
Indication: adrenal insufficiency (AI)
Status: Positive CHMP opinion
Industry Impact
This decision highlights important regulatory and development trends:
- Demonstrates EMA’s support for optimising labels in rare endocrine disorders
- Reinforces the value of post-authorisation lifecycle management for established medicines
- Encourages sponsors to pursue age-range and indication refinements backed by clinical evidence
- Improves regulatory clarity for specialty and rare-disease therapies in the EU
https://www.ema.europa.eu/en/medicines/human/variation/efmody